---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-141462"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:16:01.420648+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M

## Summary
- JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.
- Net loss $30.2M ($1.30 per share) vs $28.4M ($1.25 per share) in Q1 2022.
- Cash and marketable securities $75.2M as of March 31, 2023.
- Reiterated FY 2023 JELMYTO revenue guidance $76-86M; operating expenses $135-145M.
- Topline data from ENVISION and ATLAS trials for UGN-102 expected summer 2023; NDA submission planned for 2024.

## SEC filing metadata
- accession: 0001193125-23-141462
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/0001193125-23-141462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/d365198d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-141462
- JSON: https://secwatch.observer/filing/0001193125-23-141462.json
- Plain text: https://secwatch.observer/filing/0001193125-23-141462.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the first quarter ended March 31, 2023 results: revenue $17.2 million, net income $30.2 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $17.2 million
  - Net income: $30.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: 99.1 UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments • Reported JELMYTO ® Q1 2023 net product revenues of $17.2 million, an increase of ~27% from Q1 2022 • Complete Response data from ENVISION pivotal trial and topline data readout from ATLAS trial on track for summer 2023 PRINCETON, N.J. May 11,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/0001193125-23-141462-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.